Anti-mouse CD19-InVivo [1D3]

製品コード：A2149         Batch: A214904

印刷

Anti-mouse CD19-InVivo [1D3] reacts with mouse CD19, a B cell-specific 95 kDa transmembrane glycoprotein of the immunoglobulin superfamily.

製品説明

Formulation PBS, pH 7.0 Contains no stabilizers or preservatives
Clone 1D3
Isotype Rat IgG2a, κ
Application Anti-mouse CD19-InVivo
Source CHO
Murine Pathogen Screening Panel all targets tested yielded Negative Results: Theiler’s Murine Encephalomyelitis Virus, Ectromelia (Mousepox) Virus, Hantavirus, Polyomavirus, Sendai Virus, Mycoplasma pulmonis, Pneumonia Virus of Mice, K Virus, Mouse Parvovirus, Mouse Hepatitis Virus, Mouse Norovirus, Mouse Minute Virus, Mouse Cytomegalovirus, Mouse Adenovirus, Lactate Dehydrogenase-Elevating Virus, Reovirus Panel, Lymphocytic Choriomeningitis Virus, Mouse Rotavirus.
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Shipping Shipped under low temperature conditions
Sterility 0.2 μM filtered
Purity 99%
Protein concentration 5.89 mg/ml
Endotoxin Level ＜1EU/mg

カスタマーフィードバック

A2149-Anti-mouse-CD19-InVivo.gif

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Anti-BCL2 therapy eliminates giant congenital melanocytic nevus by senolytic and immune induction [ Signal Transduction and Targeted Therapy, May 16, 2025, 10(1):161] PubMed: 40374605
Oncolytic virus M1 reinvigorates CD8+ T-cell immunity against glioblastoma through B-cell-dependent antigen cross-presentation in the spleen [ Cellular and Molecular Immunology, March 4, 2026, 23(4):349-366] PubMed: 41781696
Anti-BCL2 therapy eliminates giant congenital melanocytic nevus by senolytic and immune induction [ Signal Transduction and Targeted Therapy, 2025 May 16, 10(1):161] PubMed: 40374605
Anti-BCL2 therapy eliminates giant congenital melanocytic nevus by senolytic and immune induction [ Signal Transduct Target Ther, 2025, 10(1):161] PubMed: 40374605

人間や獣医の診断であるか治療的な使用のためにでない。